Viewing Study NCT00446602


Ignite Creation Date: 2025-12-25 @ 3:49 AM
Ignite Modification Date: 2026-05-16 @ 4:59 AM
Study NCT ID: NCT00446602
Status: WITHDRAWN
Last Update Posted: 2016-09-20
First Post: 2007-03-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Anemia View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PROCRIT View
None Epoetin alfa View
None Myelodysplastic Syndromes View
None MDS View